Intellia discontinues ex vivo programs and cuts workforce to focus on nex-z and lonvo-z

Intellia Therapeutics

Intellia prioritized its two late-stage in vivo programs—NTLA-2002 (lonvo-z for hereditary angioedema) and nex-z (for transthyretin amyloidosis)—for 2025. It discontinued NTLA-3001 for alpha-1 antitrypsin deficiency, some research programs, and planned a net workforce reduction of about 27%.

• In-vivo focus: lonvo-z (hereditary angioedema Phase 3 HAELO) and nex-z (ATTR amyloidosis).
• Discontinued: NTLA-3001 (AATD), select research-stage programs.
• Workforce reduction: ~27% net reduction during 2025.
• MAGNITUDE study enrollment target: at least 550 patients by year-end 2025.